Checkmate Awaiting Strategy: Unlocking the Potential of Chimeric Antigen Receptor T-cell Therapy in Uveal Melanoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Mar 5

PMID 40040721

Authors

Ahmed H Al Sharie

Samah O Al-Omari

Abdelwahab Aleshawi

Rami Al-Dwairi

Osama Al Deyabat

Affiliations

Soon will be listed here.

References

Nayman T, Bostan C, Logan P, Burnier Jr M . Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses. Curr Eye Res. 2017; 42(8):1085-1093. DOI: 10.1080/02713683.2017.1297997. View

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

Hackett C, Hirschhorn D, Tang M, Purdon T, Marouf Y, Piersigilli A . TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models. Mol Ther Oncol. 2024; 32(3):200862. PMC: 11415964. DOI: 10.1016/j.omton.2024.200862. View

Ventin M, Cattaneo G, Arya S, Jia J, Gelmi M, Sun Y . Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Clin Cancer Res. 2024; 30(15):3243-3258. PMC: 11572477. DOI: 10.1158/1078-0432.CCR-24-0071. View

Forsberg E, Lindberg M, Jespersen H, Alsen S, Olofsson Bagge R, Donia M . HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Res. 2019; 79(5):899-904. DOI: 10.1158/0008-5472.CAN-18-3158. View

Khan S, Almalki W, Arora S, Kesharwani P . Recent approaches for the treatment of uveal melanoma: Opportunities and challenges. Crit Rev Oncol Hematol. 2023; 193:104218. DOI: 10.1016/j.critrevonc.2023.104218. View

Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S . The biology of uveal melanoma. Cancer Metastasis Rev. 2017; 36(1):109-140. PMC: 5385203. DOI: 10.1007/s10555-017-9663-3. View

Wespiser M, Neidhardt E, Negrier S . Uveal melanoma: In the era of new treatments. Cancer Treat Rev. 2023; 119:102599. DOI: 10.1016/j.ctrv.2023.102599. View

Carvajal R, Sacco J, Jager M, Eschelman D, Olofsson Bagge R, Harbour J . Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023; 20(2):99-115. DOI: 10.1038/s41571-022-00714-1. View

10.

Sorrentino F, Culiersi C, Florido A, De Nadai K, Adamo G, Nasini F . Genetic Features of Uveal Melanoma. Genes (Basel). 2024; 15(11). PMC: 11593461. DOI: 10.3390/genes15111356. View

11.

Soltantoyeh T, Akbari B, Karimi A, Chalbatani G, Ghahri-Saremi N, Hadjati J . Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells. 2021; 10(6). PMC: 8230324. DOI: 10.3390/cells10061450. View

12.

Jilani S, Saco J, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C . CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024; 15(1):1244. PMC: 10858182. DOI: 10.1038/s41467-024-45221-2. View